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Abstract 
SARS-CoV-2 as an emerging coronavirus, which first emerged in late 2019 in China causes a respiratory disease 
called “Coronavirus Disease 2019 (COVID-19)’’. SARS-CoV-2 has since infected more than 26 million people 
worldwide and caused more than 864000 deaths as of September 04, 2020. The SARS-CoV-2 spike (S) protein 
consists of two subunits: S1 and S2, which plays a role in binding to cellular receptors and mediating the fusion 
process between the membranes of the virus and host cells. The S protein has an important role to induce neutralizing-
antibody, as well as protective immunity, during SARS-CoV-2 infection. In this review, we focused on different types 
of the vaccine against COVID-19. 
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Introduction 
Nidovirales order is divided into three viral families 
including Coronaviridae, Arteriviridae, and 
Roniviridae. Coronaviridae as a large enveloped 
family is classified into four genera: alpha-
coronavirus, beta-coronavirus, gamma-coronavirus, 
and delta-coronavirus (1). To date, six human 
coronaviruses (HCoVs) have been identified 
including HCoVs-229E, HCoVs-NL63, HCoVs-
HKU-1, HCoVs-OC43, severe acute respiratory 
syndrome-CoV (SARS-CoV), and Middle East 
respiratory syndrome-CoV (MERS-CoV) that are 
members of alpha- and beta-coronaviruses (2). In 
December 2019, the novel coronavirus called 
SARS-CoV-2 was reported in Wuhan, China (3). 
Base on genetic analysis, SARS-CoV-2 belongs to 
beta-coronavirus genera. The symptoms of 
Coronavirus Disease 2019 (COVID-19), a disease 
caused by SARS-CoV-2, include fever, coughing, 
and shortness of breath; it can cause lung damage 
and acute respiratory distress syndrome and lead to 
lung disorders and death (4,5). 
COVID-19 has spread rapidly around the world and 
posed a serious threat to public health. On 11 March 
2020, the world health organization announced 
COVID-19 outbreak had turned into a pandemic 
(6,7). The origin of SARS-CoV-2 remains unknown 
yet; however, some studies have shown that animals 
such as bats, pangolins, snakes may be the potential 
hosts for this emerging virus (8). The genome 
analysis of SARS-CoV-2 reveals similarity to other 
beta-coronaviruses, which are found in bats. The 
genome sequence of SARS-CoV-2 is 96.2% similar 
to bat coronavirus (RaTG13), however, the SARS-
CoV-2 genome shares 79.5% identity with SARS-
CoV (5, 9). Such findings indicate that SARS-CoV-
2 may actually has been derived from bats and 
transmitted to other non-human species over time 
and has recently been transferred to humans. 
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Currently, patients and carriers are the most 
important source of COVID-19. Prevalence and 
spreading speed of SARS-CoV-2 are higher than 
SARS-CoV therefore it has high transmission 
capacity in comparison with SARS-COV in the 
population (10). SARS-CoV-2 is transmitted via a 
variety of pathways including person to person 
(direct contact) through respiratory droplets, and 
indirect contact through fomites and aerosols (11). 
Some common symptoms of COVID-19 including 
fever of about 38C, headache, cough, sore throat, 
fatigue, myalgia, and shortness of breath. Some 
patients with COVID19 have also reported 
gastrointestinal disorders such as diarrhea and 
vomiting (12). The mortality rate of SARS-CoV-2 
depends on the severity of the disease. According to 
reports, the incubation period of the COVID-19 is 
one to 14 days and in most cases between 3 to 7 
days (13). In general, all people are susceptible to 
SARS-CoV-2, although older people and people 
with underlying diseases are high-risk groups (14). 
SARS-CoV-2 can also infect children and infants, 
but symptoms in children are relatively mild which 
may be due to children’s immune system functions 
(15).  
SARS-CoV-2 genome 
The genome of SARS-CoV-2 is approximately 30 
kb (16). The 5′ end of the genome has an extended 
ORF1ab polyprotein, which produces non-structural 
proteins, although structural proteins are encoded in 
the 3′ end of the genome (17). As shown in 
(Figure 1) major structural proteins including the 
spike (S), membrane (M), envelope (E), and the 
nucleocapsid (N) protein (18).  
SARS-CoV-2 utilizes angiotensin-converting 
enzyme 2 (ACE2) as the cellular receptor on the 
host cell for the binding and entry process, leading 
to severe respiratory disease (19). 
Structure of the SARS-CoV-2 spike protein 
SARS-COV-2 synthesizes spike glycoprotein as a 
single chain precursor that forms a trimer structure 
upon folding process, S glycoprotein belongs to 
class I viral fusion proteins such as hemagglutinin 
(HA) of influenza, paramyxovirus fusion (F) 
protein, ebolavirus glycoprotein 28 (GP), and 
glycoprotein 160 of HIV (20, 21). The molecular 
weight of each monomer of S glycoprotein is about 
180 kDa and contains 1273 amino acids (22, 23).  
SARS-CoV-2 spike glycoprotein is a structural 
protein consisting of S1 and S2 subdomains. The S1 
domain sequence is variable and responsible for 
binding to ACE2 as a cellular receptor, and the S2 
domain with a conserved sequence has an important 
role in integrating the viral membrane into the cell 
membrane (24). 
 
Figure 1. The overall structure Schematic of SARS-
CoV-2. 
SARS-CoV-2 and SARS-CoV utilize angiotensin-
converting enzyme 2 (ACE2) to enter into the target 
cell where the virus replicates and spreads into 
other cells in the respiratory tract, SARS-CoV-2 
binds to ACE2 through S glycoproteins (25). 
Amino acid 493 in the receptor-binding domain 
(RBD) of S protein has a vital role in the binding to 
ACE2 (3).  
Computer analysis showed similar 3-D structures in 
the receptor-binding domain in S glycoprotein of 
both of SARS-CoV and SARS-CoV-2 (26), 
however, S glycoprotein of SARS-CoV-2 has a 
greater affinity to human ACE2 than SARS-CoV 
spike protein and it can play an effective role in 
transmitting the SARS-CoV-2 (3). There is a high 
degree of homology between S glycoproteins of 
SARS-CoV-2 and SARS-CoV, which in their S 
proteins display a sequence similarity of 75% (27). 
To bind the virus to the ACE2 receptor, an 
interaction between glutamine in the position of 
residue 394 in the SARS-CoV-2 spike protein and 
lysine 31 is necessary (28). Entry to the host cell is 
a vital step for virus replication, thus, ACE2 as a 
cellular receptor has an important role in both 
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SARS-CoV and SARS-CoV-2 replication cycle 
(29). 
Recent studies showed that there is a mutation in 
the carboxyl-terminal region of the S1 domain of 
SARS-CoV-2 spike protein which can increase viral 
infectivity and transmission from person to person 
(30).  
SARS-CoV-2 isolates which encode a D614G 
(SG614 to SD614) mutation in S glycoprotein make a 
novel specific cleavage site for cellular protease 
which can affect infectivity, transmission, and 
severity of COVID-19 (31), therefore S 
glycoprotein can be a potential candidate for 
vaccine developing against SARS-CoV-2 
worldwide (32). 
In binding to the cellular receptor and membrane 
fusion, the essential roles of spike glycoprotein 
show that vaccines based on surface spike 
glycoprotein as a possible target will induce 
neutralizing antibodies to inhibit the process of 
virus binding and fusion (24). Spike glycoprotein 
has high immunogenicity among all structural 
proteins of SARS-CoV-2 that is responsible for 
inducing protective immunity against viral 
pathogenicity (33). 
Vaccine design based on SARS-CoV-2 genome 
Recently vaccine technology has significantly 
developed including the development of DNA and 
RNA vaccines, recombinant protein vaccines, 
vectored vaccines, and cell-culture-based vaccines 
(34).  
To monitor the continuing COVID-19 pandemic 
triggered by the emergence of SARS-CoV-2, there 
is now an urgent need for a vaccine.  
Spike glycoprotein of SARS-CoV-2 is a surface 
protein that facilitates entry of the virus into the 
host cells by binding to ACE2 as a cellular receptor, 
thus S glycoprotein can be an attractive vaccine 
target (35).  
The viral life cycle is dependent on the interaction 
between S glycoprotein and ACE2, however, 
neutralizing antibodies target the spike glycoprotein 
and can lead to interference with SARS-CoV-2 
binding to host cell, thus virus entry process and 
subsequent it’s pathogenicity are inhibited (26). 
Whole virus vaccines  
The development of vaccines against COVID-19 
can be facilitated by using experiences from efforts 
for designing vaccines against other emerging 
coronaviruses such as MERS and SARS (36). 
Different factors such as effectiveness, safety, the 
possibility of antibody-dependent enhancement 
(ADE), and other adverse effects before detection in 
MERS and SARS vaccines should be considered in 
experiments to design and develop an appropriate 
vaccine against COVID-19 (37). 
According to the WHO, there are more than 130 
candidate vaccines in five platforms for COVID-19 
in clinical and preclinical evaluation (as of August 
10, 2020) (Table 1) (38). Platforms of vaccines in 
the clinical evaluation are different including non-
replicating viral vector, inactivated, DNA, and 
RNA. Due to its high immunogenicity and 
activation of toll-like receptors (TLRs) such as 
TLR3, TLR7/8, and TLR9, the inactivated or live-
attenuated whole-virus vaccine strategy has been 
used for decades. Nonetheless, long-term 
monitoring is needed to assess its safety profile due 
to its viable nature. Many efforts are being made by 
some companies on the SARS-CoV-2 whole 
vaccine candidate due to the introduction of codon 
deoptimization technology for attenuating viruses 
(39). 
Non-replicating viral vector 
Viral vectors for both non-replicating and 
replicating forms are available including poxviruses 
and adenoviruses. Vectors designed primarily as 
replication-defective include adeno-associated 
virus, herpesvirus, and alphavirus. In fact, there are 
some advantages and disadvantages in Non-
Replicating Viral Vectors like adenovirus that are 
used for a vaccine against SARS-CoV-2. They 
target mucosal inductive sites, infect dividing, non-
dividing, and dendritic cells, and are physically and 
genetically stable without any integration. In 
addition, there are some disadvantages like; prior 
immunity to Ad5 and high doses needed to elicit 
immunity (40). Generally, pre-existing immunity to 
the Ad5 vector and increasing age could partially 
hamper the specific immune responses to 
vaccination; particularly the humoral immune 
responses are typically delayed. In this way, 
ChAdOx1-S, developed by the University of 
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Oxford in partnership with AstraZeneca, is the first 
vaccine candidate to reach phase III clinical trials 
(41).  
A study has reported that a single dose of the 
vaccine can elicit a strong immune response in 
rhesus macaques (42). In addition, an experimental 
study in pigs showed that when given a booster 
dose, ChAdOx can elicit a higher antibody level, 
indicating that a double-dosing procedure can 
provide better protection in humans. ChAdOx1-S 
was well tolerated in humans, with no strong 
adverse effects seen in a sample of more than 320 
vaccinated individuals (43). 
Table 1. Candidate Vaccines in Clinical Evaluation 
Platform Type of candidate vaccine 
The current 





ChAdOx1-S1 Phases 1/2, 2b, 3 University of Oxford/Astra Zeneca 
Adenovirus Type 5 Vector Phases 1, 2 
CanSino BiologicalInc/ Beijing 
Institute of Biotechnology 
Adeno based Phase 1 Gamaleya ResearchInstitute 
Inactivated viral 
products 
Inactivated+ alum Phase 3 Sinovac 
Inactivated Phases 1, 2 
Wuhan Institute of Biological 
Products/Sinopharm 
Inactivated Phases 1, 2 
Beijing Institute of Biological 
Products/Sinopharm 
Inactivated Phase 1 
Institute of Medical Biology, Chinese 
Academy of Medical Sciences 
DNA 
DNA plasmid vaccine with 
electroporation 
Phases 1, 2 
Inovio Pharmaceuticals/International 
Vaccine Institute 
DNA plasmid vaccine Phases 1, 2 Cadila Healthcare Limited 
DNA Vaccine (GX-19) Phase 1 Genexine Consortium 
RNA 
LNP2 encapsulated mRNA Phases 1, 2 Moderna/NIAID 
3 LNP-mRNAs Phases 1, 2 BioNTech/Fosun Pharma/Pfizer 
Recombinant 
Protein Subunit 
Full length recombinant SARS 
CoV-2 glycoprotein nanoparticle 
vaccine adjuvanted with Matrix M 
Phases 1, 2 Novavax 
1 Recombinant Chimpanzee Adenovirus Vector, 2 Lipid Nanoparticle. 
 
Inactivated viral products 
For the past 70 years, inactivated vaccines have 
been successfully used and are used commonly 
today.  
In general, immunity caused by inactivated or 
subunit vaccines is more limited in length. A key 
factor in the pursuit of the latter approaches is 
safety. Concerns arise not only over the possibility 
of disease induction in vaccinated individuals, 
particularly those who are immune-compromised, 
but also over the spread of the vaccine virus in the 
population.  
Regarding inactivated viral products in Table 1, 
Sinovac Biotech has demonstrated protection by 
PiCoVacc against SARS-CoV-2 in monkeys. 
Monkeys were immunized three times with two 
different doses (3 or 6 μg per dose) of PiCoVacc at 
days 0, 7, and 14 before the virus challenge in the 
third week.  
One study showed that monkeys vaccinated against 
SARS-CoV-2 with PiCoVacc, produced SARS-
CoV-2 neutralizing antibody titers similar to those 
of recovered patients. This study also showed that 
PiCoVacc is safe because no infection enhancement 
or immunopathological exacerbation was observed 
in vaccinated monkeys (44). 
Recombinant protein subunit 
The protection and immunogenicity study of the 
Novavax SARS-CoV-2–3Q-2P-FL immunogenic in 
mice and baboons revealed strong B- and T-cell 
responses to the vaccine without evidence of 
vaccine-associated enhanced respiratory disease 
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(VAERD) (45). This advanced protein subunit 
vaccine candidate currently being tested in humans 
appears stable, homogeneous, and locked in the 
antigenically preferred perfusion conformation (46). 
World’s first COVID-19 vaccine 
The Sputnik V as a viral vector vaccine against 
COVOD-19 was developed by Gamaleya research 
institute. The same methods which were used for 
the Ebola vaccine have been also used for Sputnik 
V. Viral vectors are a relatively new technology for 
vaccine design. There have been several large 
clinical trials with viral vectors for Tuberculosis, 
Malaria, HIV, and Ebola, however, only one for 
Ebola has ever been approved for use in the general 
population (47). According to the Russian Ministry 
of Health, it is expected that the sputnik vaccine 
provides immunity from SARS-CoV-2, the virus 
that causes COVID-19, for up to two years. Sputnik 
V consists of two serotypes of human adenovirus 
and it is administered in two doses, each carrying an 
S-antigen of the SARS-CoV-2, which can enter into 
human cells and produce an immune response. 
Conclusion 
SARS-CoV-2 as a contagious agent quickly spreads 
all over the world. Among structural proteins of 
SARS-CoV-2, S protein has key roles in the 
binding and membrane fusion process, suggesting 
that S protein-based vaccines can activate 
antibodies to block virus infection. Therefore, S 
protein can be selected as an important target for 
vaccine and antiviral development.  As mentioned 
above, S glycoprotein is the main component for 
the development of vaccines against SARS-CoV-2 
infection. Full-length S protein can induce T-cell 
responses and neutralizing-antibodies, however, it 
might cause enhance infection or liver damage via 
harmful immune responses. The RBD of S 
glycoprotein induces neutralizing antibodies to 
block virus binding and membrane fusion process 
thus can inhibit the pathogenicity of SARS-CoV-2. 
Currently, vaccines that use viral DNA, mRNA, and 
micro genes are being studied in Phase I and 
Phase II clinical trials. Numerous ongoing clinical 
trials demonstrate that the science community is 
working actively to overcome this problem. As 
vaccines and specialized medications are not 
successful, prevention seems to be the best way to 
reduce the transmission of the virus. 
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